Nephrobesity describes the study and care of kidney disease as it relates to obesity. It is an emerging clinical focus — not an accredited board subspecialty — that sits deliberately across two disciplines historically managed apart.
A bidirectional relationship
Obesity and kidney disease drive each other. Excess adiposity raises glomerular pressure and filtration, activates the renin–angiotensin system, and promotes the inflammation and insulin resistance that injure the nephron over years. Kidney disease, in turn, alters metabolism, appetite regulation, and the safe use of weight-management therapies.
Obesity-related glomerulopathy (ORG)
The most direct kidney lesion of obesity is obesity-related glomerulopathy: glomerulomegaly with an adaptive form of focal segmental glomerulosclerosis, driven by hyperfiltration. It typically presents with slowly rising proteinuria and preserved albumin. It can be misclassified as primary FSGS when the biopsy pattern is read without integrating clinical context, albumin level, the absence of nephrotic syndrome, and the hyperfiltration phenotype. Not all obesity-associated CKD is ORG.
The cardiovascular-kidney-metabolic (CKM) framework
Contemporary guidelines organise these conditions as a single continuum — cardiovascular-kidney-metabolic health — introduced in the AHA 2023 Presidential Advisory (staging system, stages 0 through 4) and formalised in the first multisociety AHA/ACC/ADA/ASN CKM guideline (2026).
The therapeutic turn — and the renal-safety gap
Semaglutide (in the FLOW trial), SGLT2 inhibitors, and the non-steroidal mineralocorticoid-receptor antagonist finerenone each moved to renoprotective therapies backed by dedicated outcome trials. Kidney-outcome evidence is agent- and endpoint-specific and should not be generalised to the whole GLP-1 class. Dual GIP/GLP-1 agonists show emerging renal signals; triple agonists and amylin analogs remain investigational. Together these support an emerging multi-pillar approach — RAAS blockade, SGLT2 inhibition, non-steroidal MRA where indicated, and incretin therapy in selected patients.
Where the field is anchored
CKM framework (AHA 2023 advisory; AHA/ACC/ADA/ASN 2026 guideline); KDIGO Obesity–CKD Controversies Conference (Prague 2024; Kidney International 2025); ASN Kidney Health Guidance on obesity (JASN 2024;35(11):1574–1588). Pivotal trials: FLOW, SELECT, SURPASS-4, finerenone (FIDELIO-DKD / FIGARO-DKD).
Go deeper: the ten clinical domains →